Clinical Trial

hepatomiR cACLD Study

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated September 9, 2025 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
This study looks to gather data on hepatomiR, a CE-certified test already intended for gauging liver-related outcomes, in order to define a cut-off regarding specific decompensation events (ascites, variceal hemorrhage, hepatic encephalopathy) in chronic liver disease (CLD). Based on these data, it is aimed to advance the current understanding of factors driving decompensation, with potential repercussions for future risk management and therapy.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-05-24.
Trial Details
NCT Number NCT06432582
Lead Sponsor Karl Landsteiner University of Health Sciences
Collaborators: University Hospital St. Polten
Conditions Chronic Liver Disease and Cirrhosis, Chronic Liver Disease, Portal Hypertension
Enrollment 156 participants
Start Date 2024-05-15
Primary Completion 2026-06 (estimated)
Study Completion 2026-06 (estimated)
Updated on ClinicalTrials.gov 2025-09-09